论文部分内容阅读
68例新接受肾移植的患者应用新山地明胶囊，其用量比山地明减少16.64％，全血浓度谷值维持稳定[3个月平均值（318．46±7826）μg／L]，仅1例发生急性排斥反应，4例发生肝毒性，3例发生肾毒性。18例由山地明或国产环孢素转换为新山地明的患者，免疫抑制效果满意，无排斥反应和明显的药物毒副作用，仅1例开始转换后出现过血肌研值升高。说明新山地明的生物利用度高，药物代谢动力学稳定，临床应用免疫抑制效果比山地明好。
68 cases of patients who received new kidney transplantation were treated with Xin Shan Di Ming Capsules, the dosage of which was 16.64% less than that of Shan Ming Ming. The whole blood concentration valley remained stable [3 months (318.46 ± 7826) μg / L], only 1 Acute rejection occurred in 4 cases, liver toxicity in 4 cases and nephrotoxicity in 3 cases. 18 cases of patients who were switched from mountain or domestic cyclosporine to nornicotine had satisfactory immunosuppressive effect, no rejection and obvious side effects of drugs. Only 1 patient had a trans-hemodialysis value after the start of conversion. It shows that the bioavailability of neo-Yamatake is high and its pharmacokinetics are stable. The immunosuppressive effect of clinical application is better than that of mountainous area.